Thu, December 15th 2022
ProtonDx Revs Up European Commercial Expansion with New Head of Sales
Leigh Howes brings more than 20 years diagnostics sector experience. Track record of commercial success across Europe.
London, UK – 15 December 2022 – Today, ProtonDx, an in vitro diagnostics company designing, manufacturing and marketing rapid, accurate, multi‑pathogen, point‑of‑need diagnostic solutions, announced the appointment of its new Head of Sales, Leigh Howes.
Howes is a commercially astute leader with more than 20 years of experience in the life science, diagnostics and clinical markets. He brings a proven track record of success to ProtonDx, delivering consistent growth, focused on achievement and a structured approach to strategy deployment.
As leader of the Commercial Sales team, Howes will have a pivotal role in setting‑up distribution partners and direct sales in Europe and countries that accept the CE‑IVD mark. This follows ProtonDx’s successful CE‑IVD marking for its innovative Dragonfly in vitro diagnostic system earlier this year.
Leigh Howes, Head of Sales, ProtonDx:
“I am honoured and thrilled to be joining ProtonDx, and look forward to working with a talented and highly dedicated team. By introducing molecular testing at the point‑of‑care, our flagship product, Dragonfly, delivers numerous potential benefits for healthcare professionals and caregivers ‑ ultimately improving patient outcomes. I look forward to helping realise ProtonDx and Dragonfly’s huge potential and to build on the Company’s existing successes while solidifying its position as a significant commercial player.”
Bob Enck, Chairman and President of ProtonDx, stated:
“We are thrilled to welcome Leigh to the team, as a senior leader in a world‑class organization with an innovative, disruptive technology. He has demonstrated execution success and the ability to inspire a culture of excellence, accountability, and trust, all of which will be critical as we scale the organisation and increase our commercial focus. We look forward to supporting Leigh, as he focuses on cross‑functional commercial opportunities across Europe to achieve rapid sales growth.”
Dragonfly is a portable, rapid molecular diagnostic system able to identify multiple viral pathogens at the point of need. Its revolutionary approach allows severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), influenza A virus (IAV), influenza B virus (IBV), respiratory syncytial virus (RSV) and human rhinovirus (HRV) to be detected in a single test. The system is poised to help revolutionise rapid infectious disease detection and tracking worldwide.